Sandoz Canada Negotiated with Pan-Canadian Pharmaceutical Alliance (pCPA) to Launch Ziextenzo (biosimilar, pegfilgrastim) and Riximyo (biosimilar, rituximab) in Canada

Shots:

• In Jul 2020, following the pCPA agreement Riximyo is now reimbursed through Limited Use as well as the Exceptional Access Program while funding will be done by Cancer Care Ontario. Additionally, from Aug 01, 2020, the BC cancer will be responsible for reimbursement of Riximyo as per British Columbia
• The patient support program will be initiated to provide patients the guidance with reimbursement navigation, financial assistance, administrative support, as well as education for patients
• On Apr 28, 2020, Riximyo received HC approval a mAb or the treatment of NHL and CLL, as well as the autoimmune disease RA. On Apr 21, 2020, Ziextenzo received HC approval a long-acting form of recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) for to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive antineoplastic agents

Click here to read full press release/ article | Ref: GlobeNewswire | Image: Behance